Literature DB >> 1331249

Evidence that protection against rotavirus diarrhea after natural infection is not dependent on serotype-specific neutralizing antibody.

R L Ward1, J D Clemens, D R Knowlton, M R Rao, F P van Loon, N Huda, F Ahmed, G M Schiff, D A Sack.   

Abstract

This case-control study sought to determine whether protection against clinically significant rotavirus diarrhea in children aged 4-35 months correlated with titers of serum neutralizing antibody and, if so, whether this protection was serotype-specific. Titers of acute-phase sera from 156 cases of treated rotavirus diarrhea in rural Bangladesh were contrasted with titers from 312 contemporaneously selected, age-matched controls. Analyses of the culture-adapted rotaviruses from the cases revealed that 24%, 15%, 43%, and 17% belonged to serotypes 1-4, respectively. Titers of both homologous and heterologous neutralizing antibody in acute blood specimens of cases were significantly lower than those of matched controls. However, multivariate logistic regression models demonstrated that only antibody titers to heterotypic rotaviruses were independently associated with protection against rotavirus disease. These data, which indicate that the correlation of protection with neutralizing antibody titers is not serotype-specific, suggest that immunity to rotavirus disease may be mediated by other factors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1331249     DOI: 10.1093/infdis/166.6.1251

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

Review 1.  Immune responses to rotavirus infection and vaccination and associated correlates of protection.

Authors:  Ulrich Desselberger; Hans-Iko Huppertz
Journal:  J Infect Dis       Date:  2011-01-15       Impact factor: 5.226

2.  Serotype specificity of the neutralizing-antibody response induced by the individual surface proteins of rotavirus in natural infections of young children.

Authors:  G Menchaca; L Padilla-Noriega; M Méndez-Toss; J F Contreras; F I Puerto; H Guiscafré; F Mota; I Herrera; R Cedillo; O Muñoz; R Ward; Y Hoshino; S López; C F Arias
Journal:  Clin Diagn Lab Immunol       Date:  1998-05

3.  Comparative In Vitro and In Vivo Studies of Porcine Rotavirus G9P[13] and Human Rotavirus Wa G1P[8].

Authors:  Lulu Shao; David D Fischer; Sukumar Kandasamy; Abdul Rauf; Stephanie N Langel; David E Wentworth; Karla M Stucker; Rebecca A Halpin; Ham Ching Lam; Douglas Marthaler; Linda J Saif; Anastasia N Vlasova
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

4.  Prevention of cholestasis in the murine rotavirus-induced biliary atresia model using passive immunization and nonreplicating virus-like particles.

Authors:  Paula M Hertel; Sue E Crawford; Brooke C Bessard; Mary K Estes
Journal:  Vaccine       Date:  2013-07-22       Impact factor: 3.641

5.  Human VP8* mAbs neutralize rotavirus selectively in human intestinal epithelial cells.

Authors:  Ningguo Feng; Liya Hu; Siyuan Ding; Mrinmoy Sanyal; Boyang Zhao; Banumathi Sankaran; Sasirekha Ramani; Monica McNeal; Linda L Yasukawa; Yanhua Song; B V Venkataram Prasad; Harry B Greenberg
Journal:  J Clin Invest       Date:  2019-08-12       Impact factor: 14.808

6.  Inhibition of rotavirus replication by a non-neutralizing, rotavirus VP6-specific IgA mAb.

Authors:  Ningguo Feng; Jeffrey A Lawton; Joana Gilbert; Nelly Kuklin; Phuoc Vo; B V Venkataram Prasad; Harry B Greenberg
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

7.  Memory T-cell response to rotavirus detected with a gamma interferon enzyme-linked immunospot assay.

Authors:  Robin M Kaufhold; Jodie A Field; Michael J Caulfield; Su Wang; Heather Joseph; Melissa A Wooters; Tina Green; H Fred Clark; David Krah; Jeffrey G Smith
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

8.  Divergence of VP7 genes of G1 rotaviruses isolated from infants vaccinated with reassortant rhesus rotaviruses.

Authors:  Q Jin; R L Ward; D R Knowlton; Y B Gabbay; A C Linhares; R Rappaport; P A Woods; R I Glass; J R Gentsch
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

9.  Antibody responses to human rotavirus (HRV) in gnotobiotic pigs following a new prime/boost vaccine strategy using oral attenuated HRV priming and intranasal VP2/6 rotavirus-like particle (VLP) boosting with ISCOM.

Authors:  A M González; T V Nguyen; M S P Azevedo; K Jeong; F Agarib; C Iosef; K Chang; K Lovgren-Bengtsson; B Morein; L J Saif
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

Review 10.  Correlates of protection against human rotavirus disease and the factors influencing protection in low-income settings.

Authors:  E Clarke; U Desselberger
Journal:  Mucosal Immunol       Date:  2014-12-03       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.